Skip to main content

Advertisement

SpringerLink
Log in

Early ovarian cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Epithelial ovarian cancer may appear to be confined to the ovaries or pelvis in approximately one-third of patients at exploration, but up to 30% of them will be upstaged following surgical staging. Substage and histotype are the most important prognostic factors that determine the need for adjuvant treatment. Patients with stage Ia or Ib and well-differentiated (other than clear cell) tumors do not require adjuvant treatment. Patients with stage Ia or Ib grade 3 or clear cell histology, as well as any stage Ic and II disease, are at high risk for recurrence. Platinum-based chemotherapy is the mainstay of treatment. Four to six courses are probably adequate, although grade 3 tumors may require further treatment. Preservation of the uterus and the uninvolved contralateral ovary is a viable option in young women with unilateral early disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Buchsbaum HJ, Brady MF, Delgado G, et al.: Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 1989, 169:226–232.

    PubMed  CAS  Google Scholar 

  2. McGowan L, Lesher LP, Norris HJ, Barnett M: Misstaging of ovarian cancer. Obstet Gynecol 1985, 65:568–572.

    PubMed  CAS  Google Scholar 

  3. Leminen A, Lehtovirta P: Spread of ovarian cancer after laparoscopic surgery: report of eight cases. Gynecol Oncol 1999, 75:387–390.

    Article  PubMed  CAS  Google Scholar 

  4. Benjamin I, Morgan MA, Rubin SC: Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol 1999, 72:288–291. This study found that occult ovarian involvement was extremely uncommon in 118 patients with apparent stage 1a ovarian cancer who underwent removal of both ovaries.

    Article  PubMed  CAS  Google Scholar 

  5. Zanetta G, Chiari S, Rota S, et al.: Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 1997, 104:1030–1035. This study included 99 adequately staged patients with early ovarian cancer. With a median follow up of 7 years, 9% of patients undergoing fertility-sparing surgery and 12% of those undergoing more radical surgery recurred.

    PubMed  CAS  Google Scholar 

  6. McHale MT, DiSaia PJ: Fertility-sparing treatment of patients with ovarian cancer. Compr Ther 1999, 25:144–150.

    PubMed  CAS  Google Scholar 

  7. Tsumura N, Sakuragi N, Hareyama H, et al.: Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. Int J Cancer 1998, 79:526–530. This study found significant involvement of aortic lymph nodes superior to the inferior mesenteric artery in 115 patients with ovarian cancers who underwent systemic pelvic and aortic lymph node dissection.

    Article  PubMed  CAS  Google Scholar 

  8. Walter AJ, Magrina JF: Contralateral pelvic and aortic lymph node metastasis in clinical stage I epithelial ovarian cancer. Gynecol Oncol 1999, 74:128–129.

    Article  PubMed  CAS  Google Scholar 

  9. Munoz KA, Harlan LC, Trimble EL: Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997, 15:3408–3415. This study found that only 10% of women with presumptive stage I and II ovarian cancer received the recommended staging and treatment, primarily due to the lack of lymphadenectomy and histologic grading.

    PubMed  CAS  Google Scholar 

  10. Childers JM, Lang J, Surwit EA, Hatch KD: Laparoscopic surgical staging of ovarian cancer. Gynecol Oncol 1995, 59:25–33.

    Article  PubMed  CAS  Google Scholar 

  11. Pomel C, Provencher D, Dauplat J, et al.: Laparoscopic staging of early ovarian cancer. Gynecol Oncol 1995, 58:301–306.

    Article  PubMed  CAS  Google Scholar 

  12. Possover M, Krause N, Plaul K, et al.: Laparoscopic paraaortic and pelvic lymphadenectomy: experience with 150 patients and review of the literature. Gynecol Oncol 1998, 71:19–28. The manuscript presents a thorough review of the literature and presentation of the authors’ series of 150 laparoscopic staging procedures for gynecologic cancers.

    Article  PubMed  CAS  Google Scholar 

  13. Raymond E, Drolet Y, Marpeau L, et al.: Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 1997, 72:181–190.

    Article  PubMed  CAS  Google Scholar 

  14. Rubin SC, Jones WB, Curtin JP, et al.: Second-look laparotomy in stage I ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993, 82:139–142.

    PubMed  CAS  Google Scholar 

  15. Vergote IB, Kaern J, Abeler VM, et al.: Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993, 169:40–52.

    PubMed  CAS  Google Scholar 

  16. Brugghe J, Baak JPA, Wiltshaw E, et al.: Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment. Gynecol Oncol 1998, 68:47–53.

    Article  PubMed  CAS  Google Scholar 

  17. Young RC, Walton LA, Ellenberg SS, et al.: Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990, 322:1021–1027.

    Article  PubMed  CAS  Google Scholar 

  18. Bolis G, Colombo N, Pecorelli S, et al.: Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995, 6:887–893.

    PubMed  CAS  Google Scholar 

  19. Ozols RF: Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol 1995, 22:1–6.

    PubMed  CAS  Google Scholar 

  20. Rowinsky EK, Citardi MJ, Noe DA, Donehower RC: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 1993, 119:727–733.

    Article  PubMed  CAS  Google Scholar 

  21. Rowinsky EK: Clinical pharmacology of Taxol. J Natl Cancer Inst Monogr 1993, 15:25–37.

    PubMed  Google Scholar 

  22. Markman M: Amifostine in reducing cisplatin toxicity. Semin Oncol 1998, 25:522–524.

    PubMed  CAS  Google Scholar 

  23. Travis LB, Holowaty EJ, Bergfeldt K, et al.: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999, 340:351–357.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, University of Pennsylvania Hospital, 3400 Spruce Street, 19104, Philadelphia, PA, USA

    George Coukos MD, PhD & Stephen C. Rubin MD

Authors
  1. George Coukos MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen C. Rubin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coukos, G., Rubin, S.C. Early ovarian cancer. Curr. Treat. Options in Oncol. 1, 129–137 (2000). https://doi.org/10.1007/s11864-000-0057-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-000-0057-2

Keywords

Search

Navigation